Non-cefazolin antibiotic prophylaxis is associated with increased rates of acute infectious, medical, and surgical complications following primary total shoulder arthroplasty: a database study

一项数据库研究表明,非头孢唑林类抗生素预防与初次全肩关节置换术后急性感染、内科和外科并发症发生率增加相关。

阅读:2

Abstract

HYPOTHESIS: This study aimed to evaluate different prophylactic antibiotic regimens and risk for acute postoperative readmissions, infections, and medical complications. METHODS: This retrospective cohort study used the Premier Healthcare Database to identify patients who underwent primary elective shoulder arthroplasty procedures over the age of 18. The database was queried to identify perioperative antibiotic regimens using specific codes for cefazolin, clindamycin, and vancomycin. Patients receiving cefazolin monotherapy for prophylactic antibiotic regimen were used as a control group and multivariate logistic regression was then used to calculate odd ratios for postoperative complications within 90 days of the procedure. RESULTS: A total of 139,032 patients undergoing primary shoulder arthroplasty between 2016 and 2020 were included. Cefazolin monotherapy was the most prescribed antibiotic regimen (59.3%), followed by vancomycin and cefazolin combination therapy (23.3%), vancomycin monotherapy (8.6%), clindamycin monotherapy (5.6%), and vancomycin and clindamycin combination therapy (3.2%). Monotherapy with clindamycin or vancomycin was associated with increased risk of periprosthetic joint infection (P < .001). Vancomycin use as monotherapy or combination with another antibiotic increased the risk of postoperative acute kidney injury (P = .017-.001). CONCLUSION: Compared to vancomycin and clindamycin monotherapy, cefazolin monotherapy was associated with a lower risk of developing acute postoperative periprosthetic joint infection. The results of this study support the use of cefazolin monotherapy as the current standard for patients undergoing primary total shoulder arthroplasty.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。